anurajms/meta_analysis huggingface dataset:
MESH terms:
Ivabradine as adjuvant treatment for chronic heart failure
1. Bias; 2. Cardiovascular Agents [adverse effects, economics, *therapeutic use]; 3. Cardiovascular Diseases [mortality]; 4. Chemotherapy, Adjuvant; 5. Chronic Disease; 6. Exercise Tolerance [drug effects]; 7. Heart Failure [*drug therapy, mortality]; 8. Ivabradine [adverse effects, economics, *therapeutic use]; 9. Placebos [therapeutic use]; 10. Randomized Controlled Trials as Topic; 11. Stroke Volume;
MESH terms:
Renin inhibitors versus angiotensin converting enzyme (ACE) inhibitors for primary hypertension
1. Amides [adverse effects, therapeutic use]; 2. Angiotensin-Converting Enzyme Inhibitors [adverse effects, *therapeutic use]; 3. Antihypertensive Agents [adverse effects, *therapeutic use]; 4. Cardiovascular Diseases [epidemiology]; 5. Cause of Death; 6. Fumarates [adverse effects, therapeutic use]; 7. Heart Rate [drug effects]; 8. Irbesartan [therapeutic use]; 9. Kidney Failure, Chronic [epidemiology]; 10. Lisinopril [therapeutic use]; 11. Myocardial Infarction [epidemiology]; 12. Patient Dropouts [statistics & numerical data]; 13. Ramipril [therapeutic use]; 14. Randomized Controlled Trials as Topic; 15. Renin [*antagonists & inhibitors];
MESH terms:
Electromechanical‐assisted training for walking after stroke
1. Bias; 2. Cause of Death; 3. Combined Modality Therapy [instrumentation, methods]; 4. Confidence Intervals; 5. Electric Stimulation Therapy; 6. Equipment Design; 7. Exercise Therapy [methods]; 8. Gait; 9. Odds Ratio; 10. *Orthotic Devices; 11. Randomized Controlled Trials as Topic; 12. Robotics [*instrumentation]; 13. Stroke Rehabilitation [instrumentation, *methods]; 14. *Walking; 15. Walking Speed;
MESH terms:
PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease
1. Antibodies, Monoclonal, Humanized [*therapeutic use]; 2. Anticholesteremic Agents [therapeutic use]; 3. Cardiovascular Diseases [*prevention & control]; 4. Cause of Death; 5. Cholesterol, LDL [*blood]; 6. Cholinergic Antagonists [therapeutic use]; 7. Ezetimibe [therapeutic use]; 8. Hydroxymethylglutaryl-CoA Reductase Inhibitors [therapeutic use]; 9. Myocardial Infarction [epidemiology]; 10. *PCSK9 Inhibitors; 11. Primary Prevention [methods]; 12. Proprotein Convertase 9 [immunology]; 13. Randomized Controlled Trials as Topic; 14. Secondary Prevention [methods]; 15. Stroke [epidemiology]; 16. Time Factors;
MESH terms:
Pentoxifylline for intermittent claudication
1. Ankle Brachial Index; 2. Intermittent Claudication [*drug therapy]; 3. Pentoxifylline [*therapeutic use]; 4. Platelet Aggregation Inhibitors [*therapeutic use]; 5. Quality of Life; 6. Randomized Controlled Trials as Topic; 7. Vasodilator Agents [*therapeutic use]; 8. Walking;
MESH terms:
Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome
1. Anticoagulants [adverse effects, *therapeutic use]; 2. Antiphospholipid Syndrome [*complications]; 3. Cause of Death; 4. Factor Xa Inhibitors [therapeutic use]; 5. Hemorrhage [chemically induced]; 6. Platelet Aggregation Inhibitors [adverse effects, *therapeutic use]; 7. Randomized Controlled Trials as Topic; 8. Rivaroxaban [therapeutic use]; 9. *Secondary Prevention; 10. Stroke [mortality, *prevention & control]; 11. Thromboembolism [mortality, *prevention & control]; 12. Warfarin [therapeutic use];
MESH terms:
Vena caval filters for the prevention of pulmonary embolism
1. Anticoagulants [therapeutic use]; 2. Combined Modality Therapy [methods]; 3. Intermittent Pneumatic Compression Devices; 4. Multiple Trauma [complications]; 5. Pulmonary Embolism [mortality, *prevention & control]; 6. Randomized Controlled Trials as Topic; 7. Recurrence; 8. *Vena Cava Filters [adverse effects]; 9. Vena Cava, Inferior; 10. Venous Thrombosis [complications];
MESH terms:
Atherectomy for peripheral arterial disease
1. Acute Coronary Syndrome [mortality]; 2. Angioplasty, Balloon [*methods, mortality]; 3. Atherectomy [*methods, mortality]; 4. Cause of Death; 5. Heart Failure [mortality]; 6. Peripheral Arterial Disease [mortality, *therapy]; 7. Randomized Controlled Trials as Topic; 8. Stents;
MESH terms:
Motor imagery for gait rehabilitation after stroke
1. Bias; 2. Gait Disorders, Neurologic [etiology, *rehabilitation]; 3. Imagery, Psychotherapy [*methods]; 4. Randomized Controlled Trials as Topic; 5. Stroke [*complications]; 6. Stroke Rehabilitation [*methods]; 7. Walking Speed;
MESH terms:
Presurgery exercise‐based conditioning interventions (prehabilitation) in adults undergoing lower limb surgery for peripheral arterial disease
1. Lower Extremity [*blood supply]; 2. Peripheral Arterial Disease [*surgery]; 3. *Physical Conditioning, Human; 4. Preoperative Care [*methods];
MESH terms:
Alcohol intake reduction for controlling hypertension
1. Alcohol Drinking [adverse effects, mortality, *prevention & control]; 2. Bias; 3. Blood Pressure; 4. Cardiovascular Diseases [epidemiology]; 5. *Cognitive Behavioral Therapy; 6. Hypertension [etiology, mortality, *prevention & control]; 7. Randomized Controlled Trials as Topic;
MESH terms:
Time course for blood pressure lowering of beta‐blockers with partial agonist activity
1. Acebutolol [therapeutic use]; 2. Adrenergic beta-Agonists [therapeutic use]; 3. Adrenergic beta-Antagonists [*therapeutic use]; 4. Antihypertensive Agents [*therapeutic use]; 5. Bias; 6. Blood Pressure [*drug effects, physiology]; 7. Circadian Rhythm [*physiology]; 8. Controlled Clinical Trials as Topic; 9. Heart Rate [drug effects]; 10. Hypertension [*drug therapy, physiopathology]; 11. Pindolol [analogs & derivatives, therapeutic use]; 12. Time Factors;
MESH terms:
Citicoline for treating people with acute ischemic stroke
1. Activities of Daily Living; 2. Acute Disease; 3. Bias; 4. Brain Ischemia [complications]; 5. Cause of Death; 6. Cytidine Diphosphate Choline [adverse effects, *therapeutic use]; 7. Nootropic Agents [adverse effects, *therapeutic use]; 8. Randomized Controlled Trials as Topic; 9. Recovery of Function; 10. Stroke [*drug therapy, etiology, mortality];
MESH terms:
Modes of exercise training for intermittent claudication
1. Bias; 2. Bicycling; 3. Cardiovascular Diseases [therapy]; 4. *Exercise Test; 5. Exercise Therapy [*methods]; 6. Intermittent Claudication [*therapy]; 7. Randomized Controlled Trials as Topic; 8. Resistance Training; 9. Skiing; 10. Walk Test; 11. *Walking;
MESH terms:
Setting and techniques for monitoring blood pressure during pregnancy
1. Blood Pressure Determination [*methods]; 2. Blood Pressure Monitoring, Ambulatory [methods]; 3. Pre-Eclampsia [diagnosis, epidemiology]; 4. Pregnancy Complications, Cardiovascular [*diagnosis, epidemiology]; 5. Premature Birth [epidemiology]; 6. Randomized Controlled Trials as Topic; 7. Self Care [methods];
MESH terms:
mHealth education interventions in heart failure
1. Health Education [*methods]; 2. Health Knowledge, Attitudes, Practice; 3. Heart Failure [*therapy]; 4. Hospitalization; 5. Quality of Life; 6. Randomized Controlled Trials as Topic; 7. Self Care; 8. Self Efficacy; 9. Telemedicine [*methods]; 10. Uncertainty;
MESH terms:
Effect of alcohol on blood pressure
1. Alcohol Drinking; 2. *Alcoholic Beverages; 3. Bias; 4. Blood Pressure [*drug effects]; 5. Central Nervous System Depressants [administration & dosage, *pharmacology]; 6. Cross-Over Studies; 7. Ethanol [administration & dosage, *pharmacology]; 8. Heart Rate [*drug effects]; 9. Randomized Controlled Trials as Topic; 10. Sex Factors; 11. Time Factors;
MESH terms:
Surgery for small asymptomatic abdominal aortic aneurysms
1. Aortic Aneurysm, Abdominal [diagnostic imaging, mortality, *surgery]; 2. Aortic Rupture [epidemiology]; 3. Asymptomatic Diseases [mortality, *therapy]; 4. Cost-Benefit Analysis; 5. Endovascular Procedures; 6. Organ Size; 7. Quality of Life; 8. Randomized Controlled Trials as Topic; 9. Survival Analysis; 10. Time Factors; 11. Ultrasonography; 12. Watchful Waiting;
MESH terms:
Mechanical assist devices for acute cardiogenic shock
1. Acute Disease; 2. Coronary Care Units [statistics & numerical data]; 3. *Heart-Assist Devices [adverse effects]; 4. Length of Stay; 5. Quality of Life; 6. Renal Dialysis [statistics & numerical data]; 7. Shock, Cardiogenic [*mortality, *therapy];
MESH terms:
Mental practice for treating upper extremity deficits in individuals with hemiparesis after stroke
1. *Arm; 2. Combined Modality Therapy [methods]; 3. Imagination [*physiology]; 4. Paresis [etiology, *rehabilitation]; 5. *Practice, Psychological; 6. Randomized Controlled Trials as Topic; 7. Recovery of Function; 8. Stroke [*complications]; 9. Stroke Rehabilitation [*methods];
MESH terms:
A comparison of different antibiotic regimens for the treatment of infective endocarditis
1. Anti-Bacterial Agents [adverse effects, *therapeutic use]; 2. Endocarditis, Bacterial [*drug therapy, microbiology, mortality]; 3. Fosfomycin [adverse effects, therapeutic use]; 4. Imipenem [adverse effects, therapeutic use]; 5. Levofloxacin [adverse effects, therapeutic use]; 6. Penicillins [adverse effects, therapeutic use]; 7. Randomized Controlled Trials as Topic; 8. Vancomycin [adverse effects, therapeutic use];
MESH terms:
Anti‐inflammatory therapy for preventing stroke and other vascular events after ischaemic stroke or transient ischaemic attack
1. Angina, Unstable [*prevention & control]; 2. Anti-Inflammatory Agents [*therapeutic use]; 3. Heart Arrest [*prevention & control]; 4. Ischemic Attack, Transient [*complications]; 5. Myocardial Infarction [*prevention & control]; 6. Plaque, Atherosclerotic [complications, drug therapy]; 7. Secondary Prevention [methods]; 8. Stroke [etiology, *prevention & control];
MESH terms:
Pharmacological, psychological and non‐invasive brain stimulation interventions for preventing depression after stroke
1. Affect; 2. Antidepressive Agents [*therapeutic use]; 3. Depression [*prevention & control]; 4. Depressive Disorder [*prevention & control]; 5. *Psychotherapy; 6. Randomized Controlled Trials as Topic; 7. Stroke [*psychology];
MESH terms:
Pharmacological treatment for Buerger's disease
1. Alprostadil [therapeutic use]; 2. Amputation, Surgical [statistics & numerical data]; 3. Aspirin [therapeutic use]; 4. Epoprostenol [analogs & derivatives, therapeutic use]; 5. Folic Acid [therapeutic use]; 6. Hematinics [therapeutic use]; 7. Iloprost [therapeutic use]; 8. Pain [drug therapy]; 9. Placebos [therapeutic use]; 10. Platelet Aggregation Inhibitors [*therapeutic use]; 11. Prostaglandins [therapeutic use]; 12. Randomized Controlled Trials as Topic; 13. Thromboangiitis Obliterans [*drug therapy, surgery]; 14. Ulcer [drug therapy];
MESH terms:
Interventions for sexual dysfunction following stroke
1. Antidepressive Agents [adverse effects, therapeutic use]; 2. Orgasm; 3. Pelvic Floor; 4. Premature Ejaculation [drug therapy, etiology]; 5. Quality of Life; 6. Randomized Controlled Trials as Topic; 7. Resistance Training [methods]; 8. Sertraline [adverse effects, therapeutic use]; 9. Sex Education [methods]; 10. Sexual Dysfunction, Physiological [etiology, rehabilitation, *therapy]; 11. Sexual Partners [psychology]; 12. Stroke [*complications]; 13. Vitamin B 12 [analogs & derivatives, therapeutic use]; 14. Vitamin B Complex [therapeutic use];
MESH terms:
Transverse versus vertical groin incision for femoral artery approach
1. *Femoral Artery; 2. Endovascular Procedures [adverse effects, methods]; 3. Groin [*surgery]; 4. Lymphatic Diseases [epidemiology, etiology]; 5. Randomized Controlled Trials as Topic; 6. Surgical Wound [*complications]; 7. Surgical Wound Infection [epidemiology, *etiology];
MESH terms:
Low molecular weight heparin for prevention of microvascular occlusion in digital replantation
1. Anticoagulants [adverse effects, *therapeutic use]; 2. Blood Coagulation Disorders [chemically induced]; 3. Fingers [blood supply, *transplantation]; 4. Heparin [therapeutic use]; 5. Heparin, Low‐Molecular‐Weight [adverse effects, *therapeutic use]; 6. Microvessels [*surgery]; 7. Peripheral Arterial Disease [epidemiology]; 8. Postoperative Hemorrhage [chemically induced]; 9. Randomized Controlled Trials as Topic; 10. Replantation [*adverse effects]; 11. Venous Insufficiency [epidemiology];
MESH terms:
Treatment of distal deep vein thrombosis
1. Anticoagulants [adverse effects, *therapeutic use]; 2. Drug Administration Schedule; 3. Hemorrhage [chemically induced, epidemiology]; 4. Leg [*blood supply]; 5. Pulmonary Embolism [epidemiology, etiology]; 6. Randomized Controlled Trials as Topic; 7. Recurrence; 8. Secondary Prevention; 9. Time Factors; 10. Venous Thromboembolism [complications, *therapy];
MESH terms:
Physical fitness training for stroke patients
1. *Physical Fitness; 2. *Stroke Rehabilitation; 3. Activities of Daily Living; 4. Exercise Therapy [*methods]; 5. Muscle Strength; 6. Oxygen Consumption; 7. Physical Functional Performance; 8. Postural Balance; 9. Randomized Controlled Trials as Topic; 10. Resistance Training; 11. Stroke [mortality]; 12. Survivors; 13. Walking [*physiology]; 14. Walking Speed [physiology];
MESH terms:
Advance care planning for adults with heart failure
1. *Advance Care Planning; 2. *Clinical Decision‐Making; 3. Advance Directives; 4. Disease Progression; 5. Family; 6. Heart Failure [*mortality]; 7. Patient Participation; 8. Quality of Life; 9. Randomized Controlled Trials as Topic;
MESH terms:
Carotid artery stenting versus endarterectomy for treatment of carotid artery stenosis
1. *Endarterectomy, Carotid; 2. *Stents; 3. Carotid Stenosis [*surgery]; 4. Myocardial Infarction [etiology, prevention & control]; 5. Randomized Controlled Trials as Topic; 6. Stroke [etiology, prevention & control]; 7. Treatment Outcome;
MESH terms:
Anticoagulant treatment for subsegmental pulmonary embolism
1. Acute Disease; 2. Anticoagulants [*therapeutic use]; 3. Dyspnea [drug therapy]; 4. Prognosis; 5. Pulmonary Embolism [*drug therapy]; 6. Randomized Controlled Trials as Topic; 7. Treatment Outcome; 8. Watchful Waiting;
MESH terms:
First‐line combination therapy versus first‐line monotherapy for primary hypertension
1. Antihypertensive Agents [adverse effects, *therapeutic use]; 2. Cardiovascular Diseases [mortality]; 3. Drug Therapy, Combination [adverse effects, methods]; 4. Essential Hypertension [*drug therapy]; 5. Randomized Controlled Trials as Topic;
MESH terms:
Dressings and topical agents for arterial leg ulcers
1. *Wound Healing; 2. Administration, Topical; 3. Arteries; 4. Bandages, Hydrocolloid; 5. Leg Ulcer [*therapy]; 6. Occlusive Dressings; 7. Ointments [*therapeutic use]; 8. Randomized Controlled Trials as Topic; 9. Varicose Ulcer [therapy];
MESH terms:
Motor neuroprosthesis for promoting recovery of function after stroke
1. Activities of Daily Living; 2. Electric Stimulation Therapy [*methods]; 3. Motor Activity [physiology]; 4. Quality of Life; 5. Randomized Controlled Trials as Topic; 6. Recovery of Function; 7. Stroke [therapy]; 8. Stroke Rehabilitation [*methods];
MESH terms:
Endovascular versus open repair of asymptomatic popliteal artery aneurysm
1. Aneurysm [*surgery]; 2. Asymptomatic Diseases; 3. Endovascular Procedures [*methods]; 4. Operative Time; 5. Popliteal Artery [*surgery]; 6. Randomized Controlled Trials as Topic; 7. Stents;
MESH terms:
Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network meta‐analysis
1. Administration, Oral; 2. Anticoagulants [*therapeutic use]; 3. Fibrinolytic Agents [therapeutic use]; 4. Hemorrhage [prevention & control]; 5. Network Meta-Analysis; 6. *Percutaneous Coronary Intervention [adverse effects]; 7. Stroke [prevention & control]; 8. Treatment Outcome; 9. Venous Thromboembolism [prevention & control];
MESH terms:
Transcatheter aortic valve implantation versus surgical aortic valve replacement for severe aortic stenosis in people with low surgical risk
1. *Transcatheter Aortic Valve Replacement [adverse effects]; 2. Aortic Valve [surgery]; 3. Aortic Valve Stenosis [mortality, *surgery]; 4. Postoperative Complications [epidemiology]; 5. Randomized Controlled Trials as Topic; 6. Risk Factors; 7. Treatment Outcome;
MESH terms:
Beta‐blockers for suspected or diagnosed acute myocardial infarction
1. Adrenergic beta‐Antagonists [*therapeutic use]; 2. Myocardial Infarction [diagnosis, *drug therapy, mortality]; 3. Quality of Life; 4. Randomized Controlled Trials as Topic; 5. Treatment Outcome;
MESH terms:
Positive airway pressure therapy for the treatment of central sleep apnoea associated with heart failure
1. Heart Failure [*complications]; 2. Positive‐Pressure Respiration [*methods]; 3. Quality of Life; 4. Randomized Controlled Trials as Topic; 5. Sleep Apnea, Central [etiology, *therapy]; 6. Sleep Apnea, Obstructive [etiology, therapy];
MESH terms:
Cognitive rehabilitation for attention deficits following stroke
1. *Attention; 2. *Cognitive Behavioral Therapy; 3. Activities of Daily Living; 4. Cognition Disorders [*etiology, *rehabilitation]; 5. Quality of Life; 6. Randomized Controlled Trials as Topic; 7. Recovery of Function; 8. Stroke [complications, *psychology]; 9. Stroke Rehabilitation;
MESH terms:
Combined proximal descending aortic endografting plus distal bare metal stenting (PETTICOAT technique) versus conventional proximal descending aortic stent graft repair for complicated type B aortic dissections
1. *Stents; 2. Aorta, Thoracic [surgery]; 3. Aortic Aneurysm, Thoracic [surgery]; 4. Blood Vessel Prosthesis Implantation [methods]; 5. Endovascular Procedures [*methods]; 6. Randomized Controlled Trials as Topic;
MESH terms:
Perioperative beta‐blockers for preventing surgery‐related mortality and morbidity in adults undergoing non‐cardiac surgery
1. Adrenergic beta‐Antagonists [*therapeutic use]; 2. Anesthesia, General [adverse effects]; 3. Arrhythmias, Cardiac [mortality, prevention & control]; 4. Bradycardia [prevention & control]; 5. Cause of Death; 6. Hypotension [mortality, prevention & control]; 7. Morbidity; 8. Myocardial Infarction [mortality, prevention & control]; 9. Perioperative Care [*methods]; 10. Postoperative Complications [mortality, *prevention & control]; 11. Quality of Life; 12. Randomized Controlled Trials as Topic; 13. Surgical Procedures, Operative [*adverse effects, mortality];
MESH terms:
Perioperative beta‐blockers for preventing surgery‐related mortality and morbidity in adults undergoing cardiac surgery
1. *Cardiac Surgical Procedures [adverse effects, mortality]; 2. Adrenergic beta‐Antagonists [adverse effects, *therapeutic use]; 3. Arrhythmias, Cardiac [mortality, prevention & control]; 4. Bradycardia [chemically induced]; 5. Cerebrovascular Disorders [mortality, prevention & control]; 6. Hypotension [chemically induced, mortality, prevention & control]; 7. Morbidity; 8. Myocardial Infarction [mortality, prevention & control]; 9. Myocardial Ischemia [mortality, prevention & control]; 10. Perioperative Care [*methods]; 11. Postoperative Complications [mortality, prevention & control]; 12. Randomized Controlled Trials as Topic;
MESH terms:
Compression therapy for treating post‐thrombotic syndrome
1. *Stockings, Compression; 2. Postthrombotic Syndrome [etiology, prevention & control, *therapy]; 3. Quality of Life; 4. Randomized Controlled Trials as Topic; 5. Venous Thrombosis [complications];
MESH terms:
Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation
1. Anti‐Arrhythmia Agents [*therapeutic use]; 2. Atrial Fibrillation [*prevention & control]; 3. Electric Countershock; 4. Randomized Controlled Trials as Topic; 5. Recurrence; 6. Secondary Prevention;
MESH terms:
Interventions for visual field defects in people with stroke
1. Quality of Life; 2. Randomized Controlled Trials as Topic; 3. Stroke [*complications]; 4. Vision Disorders [etiology, *rehabilitation]; 5. Visual Fields;
MESH terms:
Stem cell transplantation for ischemic stroke
1. *Stem Cell Transplantation [methods]; 2. Brain Ischemia [*therapy]; 3. Randomized Controlled Trials as Topic; 4. Stroke;
MESH terms:
Prostacyclin for pulmonary arterial hypertension
1. Antihypertensive Agents [*therapeutic use]; 2. Dyspnea [drug therapy]; 3. Epoprostenol [*therapeutic use]; 4. Exercise Tolerance; 5. Hypertension, Pulmonary [*drug therapy]; 6. Quality of Life;
MESH terms:
Non‐invasive positive pressure ventilation (CPAP or bilevel NPPV) for cardiogenic pulmonary oedema
1. *Hospital Mortality; 2. Continuous Positive Airway Pressure [adverse effects, *methods]; 3. Intensive Care Units; 4. Intubation, Intratracheal [statistics & numerical data]; 5. Length of Stay; 6. Noninvasive Ventilation; 7. Pulmonary Edema [*therapy]; 8. Randomized Controlled Trials as Topic;
MESH terms:
Epidural analgesia for adults undergoing cardiac surgery with or without cardiopulmonary bypass
1. *Cardiac Surgical Procedures [adverse effects, mortality]; 2. Analgesia, Epidural [*adverse effects, methods, mortality]; 3. Anesthesia, General [*adverse effects, methods, mortality]; 4. Arrhythmias, Cardiac [prevention & control]; 5. Coronary Artery Bypass [adverse effects, mortality]; 6. Myocardial Infarction [*etiology]; 7. Randomized Controlled Trials as Topic; 8. Respiration Disorders [etiology]; 9. Stroke [*etiology];
MESH terms:
Calcium antagonists for acute ischemic stroke
1. Acute Disease; 2. Brain Ischemia [*drug therapy, mortality]; 3. Calcium [metabolism]; 4. Calcium Channel Blockers [administration & dosage, adverse effects, *therapeutic use]; 5. Flunarizine [administration & dosage, adverse effects, therapeutic use]; 6. Isradipine [administration & dosage, adverse effects, therapeutic use]; 7. Nimodipine [administration & dosage, adverse effects, therapeutic use]; 8. Randomized Controlled Trials as Topic; 9. Stroke [*drug therapy]; 10. Vasodilator Agents [administration & dosage, *therapeutic use];
MESH terms:
Exercise‐based cardiac rehabilitation for adult patients with an implantable cardioverter defibrillator
1. *Exercise Therapy; 2. *Quality of Life; 3. Cardiac Rehabilitation [adverse effects, *methods, *psychology]; 4. Cause of Death; 5. Defibrillators, Implantable [adverse effects, *psychology]; 6. Exercise Tolerance; 7. Oxygen Consumption; 8. Randomized Controlled Trials as Topic;
MESH terms:
Thoracic endovascular repair (TEVAR) versus open surgery for blunt traumatic thoracic aortic injury
1. Aorta, Thoracic [*injuries]; 2. Endovascular Procedures [*methods, mortality]; 3. Wounds, Nonpenetrating [mortality, *surgery];
MESH terms:
Drug‐eluting balloon angioplasty versus uncoated balloon angioplasty for the treatment of in‐stent restenosis of the femoropopliteal arteries
1. *Femoral Artery; 2. *Popliteal Artery; 3. *Stents; 4. Amputation, Surgical; 5. Angioplasty, Balloon [adverse effects, *methods]; 6. Ankle Brachial Index; 7. Constriction, Pathologic [etiology, mortality, therapy]; 8. Randomized Controlled Trials as Topic; 9. Recurrence; 10. Vascular Patency;
MESH terms:
Clinically‐indicated replacement versus routine replacement of peripheral venous catheters
1. Catheter‐Related Infections [*prevention & control]; 2. Catheterization, Peripheral [adverse effects, economics, *instrumentation]; 3. Catheters, Indwelling [adverse effects]; 4. Device Removal [*standards]; 5. Guideline Adherence; 6. Incidence; 7. Phlebitis [epidemiology, etiology]; 8. Randomized Controlled Trials as Topic; 9. Thrombophlebitis [epidemiology, etiology]; 10. Time Factors;
MESH terms:
Disease management interventions for heart failure
1. Aftercare [*organization & administration]; 2. Case Management [*organization & administration]; 3. Cause of Death; 4. Chronic Disease; 5. Health Status; 6. Heart Failure [mortality, *therapy]; 7. Length of Stay; 8. Patient Readmission [*statistics & numerical data]; 9. Practice Patterns, Nurses' [organization & administration]; 10. Quality of Life; 11. Randomized Controlled Trials as Topic;
MESH terms:
Angioplasty versus stenting for infrapopliteal arterial lesions in chronic limb‐threatening ischaemia
1. *Stents [adverse effects]; 2. Angioplasty [adverse effects, *methods, mortality]; 3. Endovascular Procedures [methods]; 4. Ischemia [etiology, *therapy]; 5. Leg [*blood supply]; 6. Leg Ulcer [etiology, therapy]; 7. Peripheral Arterial Disease [*complications]; 8. Popliteal Artery; 9. Quality of Life; 10. Randomized Controlled Trials as Topic; 11. Tibial Arteries; 12. Vascular Patency;
MESH terms:
Implantable cardiac defibrillators for people with non‐ischaemic cardiomyopathy
1. *Defibrillators, Implantable [adverse effects]; 2. Cardiomyopathies [mortality, *therapy]; 3. Cause of Death; 4. Death, Sudden, Cardiac [*prevention & control]; 5. Heart Failure; 6. Hospitalization; 7. Numbers Needed To Treat; 8. Quality of Life; 9. Randomized Controlled Trials as Topic; 10. Survival Rate;
MESH terms:
Ezetimibe for the prevention of cardiovascular disease and all‐cause mortality events
1. Anticholesteremic Agents [adverse effects, *therapeutic use]; 2. Cardiovascular Diseases [mortality, *prevention & control]; 3. Cause of Death; 4. Cholesterol [blood]; 5. Cholesterol, LDL [blood]; 6. Drug Therapy, Combination; 7. Ezetimibe [adverse effects, *therapeutic use]; 8. Fenofibrate [therapeutic use]; 9. Hydroxymethylglutaryl‐CoA Reductase Inhibitors [therapeutic use]; 10. Myocardial Infarction [mortality, prevention & control]; 11. Randomized Controlled Trials as Topic; 12. Simvastatin [adverse effects, therapeutic use]; 13. Stroke [mortality, prevention & control]; 14. Triglycerides [blood];
MESH terms:
First‐line drugs inhibiting the renin angiotensin system versus other first‐line antihypertensive drug classes for hypertension
1. Angiotensin-Converting Enzyme Inhibitors [adverse effects, *therapeutic use]; 2. Antihypertensive Agents [adverse effects, *therapeutic use]; 3. Calcium Channel Blockers [adverse effects, therapeutic use]; 4. Cause of Death; 5. Heart Failure [chemically induced, mortality, prevention & control]; 6. Hypertension [*drug therapy, mortality]; 7. Kidney Failure, Chronic [epidemiology]; 8. Myocardial Infarction [epidemiology]; 9. Randomized Controlled Trials as Topic; 10. Renin-Angiotensin System [*drug effects]; 11. Sodium Chloride Symporter Inhibitors [adverse effects, therapeutic use]; 12. Stroke [chemically induced, prevention & control];
MESH terms:
Stem cell therapy for treatment of thromboangiitis obliterans (Buerger's disease)
1. *Bandages; 2. *Bone Marrow Transplantation; 3. Thromboangiitis Obliterans [*therapy]; 4. Walk Test; 5. Wound Healing;
MESH terms:
Gamma aminobutyric acid (GABA) receptor agonists for acute stroke
1. Acute Disease; 2. Chlormethiazole [adverse effects, *therapeutic use]; 3. Diazepam [adverse effects, *therapeutic use]; 4. Disorders of Excessive Somnolence [chemically induced]; 5. GABA Agonists [adverse effects, *therapeutic use]; 6. Neuroprotective Agents [adverse effects, *therapeutic use]; 7. Randomized Controlled Trials as Topic; 8. Rhinitis [chemically induced]; 9. Stroke [*drug therapy, mortality]; 10. gamma‐Aminobutyric Acid [*therapeutic use];
MESH terms:
Percutaneous vascular interventions versus intravenous thrombolytic treatment for acute ischaemic stroke
1. *Thrombectomy [instrumentation, methods]; 2. Carotid Artery Thrombosis [drug therapy, surgery]; 3. Infarction, Middle Cerebral Artery [drug therapy, surgery]; 4. Intracranial Hemorrhages [epidemiology]; 5. Outcome Assessment, Health Care; 6. Randomized Controlled Trials as Topic; 7. Stroke [*drug therapy, etiology, mortality, *surgery]; 8. Thrombolytic Therapy [*methods];
MESH terms:
Very early versus delayed mobilisation after stroke
1. *Early Ambulation [adverse effects, mortality]; 2. *Stroke Rehabilitation [mortality]; 3. Activities of Daily Living; 4. Length of Stay; 5. Network Meta‐Analysis; 6. Quality of Life; 7. Randomized Controlled Trials as Topic; 8. Time Factors;
MESH terms:
Antihypertensive drug therapy for mild to moderate hypertension during pregnancy
1. Antihypertensive Agents [adverse effects, *therapeutic use]; 2. Fetal Death; 3. Hypertension [*drug therapy, prevention & control]; 4. Infant, Premature; 5. Infant, Small for Gestational Age; 6. Maternal Death; 7. Placebo Effect; 8. Pre-Eclampsia [prevention & control]; 9. Pregnancy Complications, Cardiovascular [*drug therapy, prevention & control]; 10. Proteinuria [prevention & control]; 11. Randomized Controlled Trials as Topic;
MESH terms:
Exercise‐based cardiac rehabilitation for people with implantable ventricular assist devices
1. *Exercise; 2. *Heart‐Assist Devices [adverse effects]; 3. *Resistance Training; 4. Cardiac Rehabilitation [*methods]; 5. Oxygen Consumption; 6. Quality of Life; 7. Randomized Controlled Trials as Topic;
MESH terms:
Electromechanical and robot‐assisted arm training for improving activities of daily living, arm function, and arm muscle strength after stroke
1. *Activities of Daily Living; 2. *Stroke Rehabilitation; 3. Arm; 4. Muscle Strength; 5. Robotics; 6. Stroke;
MESH terms:
Mechanical versus manual chest compressions for cardiac arrest
1. Blood Circulation; 2. Cardiopulmonary Resuscitation [instrumentation, *methods, mortality]; 3. Heart Arrest [mortality, *therapy]; 4. Heart Massage [instrumentation, *methods, mortality]; 5. Hospitalization; 6. Patient Discharge; 7. Randomized Controlled Trials as Topic;
MESH terms:
Endovascular coiling versus neurosurgical clipping for people with aneurysmal subarachnoid haemorrhage
1. *Stents; 2. Aneurysm, Ruptured [mortality, surgery, *therapy]; 3. Brain Ischemia [epidemiology, etiology]; 4. Embolization, Therapeutic; 5. Endovascular Procedures [*methods]; 6. Intracranial Aneurysm [mortality, surgery, *therapy]; 7. Neurosurgical Procedures [adverse effects, methods]; 8. Postoperative Complications [epidemiology, etiology]; 9. Randomized Controlled Trials as Topic; 10. Recurrence; 11. Secondary Prevention [methods]; 12. Subarachnoid Hemorrhage [mortality, surgery, *therapy]; 13. Treatment Outcome;
MESH terms:
Surgery versus thrombolysis for initial management of acute limb ischaemia
1. Acute Disease; 2. Amputation, Surgical [statistics & numerical data]; 3. Fibrinolytic Agents [*therapeutic use]; 4. Ischemia [mortality, surgery, *therapy]; 5. Leg [*blood supply, surgery]; 6. Limb Salvage [statistics & numerical data]; 7. Outcome Assessment, Health Care; 8. Postoperative Hemorrhage [epidemiology]; 9. Randomized Controlled Trials as Topic; 10. *Thrombolytic Therapy; 11. Time Factors; 12. Tissue Plasminogen Activator [*therapeutic use]; 13. Urokinase-Type Plasminogen Activator [*therapeutic use];
MESH terms:
Activity monitors for increasing physical activity in adult stroke survivors
1. *Exercise; 2. *Fitness Trackers; 3. *Survivors; 4. Randomized Controlled Trials as Topic; 5. Stroke Rehabilitation [*instrumentation, methods]; 6. Time Factors;
MESH terms:
Blood pressure‐lowering treatment for preventing recurrent stroke, major vascular events, and dementia in patients with a history of stroke or transient ischaemic attack
1. *Secondary Prevention; 2. Angiotensin‐Converting Enzyme Inhibitors [therapeutic use]; 3. Antihypertensive Agents [*therapeutic use]; 4. Blood Pressure [drug effects]; 5. Cardiovascular Diseases [prevention & control]; 6. Cause of Death; 7. Dementia, Vascular [*prevention & control]; 8. Diuretics [therapeutic use]; 9. Hypertension [complications, *drug therapy]; 10. Ischemic Attack, Transient [*prevention & control]; 11. Primary Prevention; 12. Randomized Controlled Trials as Topic; 13. Recurrence; 14. Stroke [etiology, *prevention & control]; 15. Systole; 16. Time Factors;
MESH terms:
Continuation versus discontinuation of antiplatelet therapy for bleeding and ischaemic events in adults undergoing non‐cardiac surgery
1. *Elective Surgical Procedures [mortality]; 2. *Withholding Treatment; 3. Aspirin [administration & dosage]; 4. Cause of Death; 5. Clopidogrel; 6. Hemorrhage [*chemically induced, therapy]; 7. Ischemia [*chemically induced, therapy]; 8. Platelet Aggregation Inhibitors [*administration & dosage]; 9. Randomized Controlled Trials as Topic; 10. Ticlopidine [administration & dosage, analogs & derivatives];
MESH terms:
Antiplatelet and anticoagulant agents for primary prevention of thrombosis in individuals with antiphospholipid antibodies
1. *Antibodies, Antiphospholipid; 2. *Primary Prevention; 3. Anticoagulants [*therapeutic use]; 4. Antiphospholipid Syndrome [*complications]; 5. Platelet Aggregation Inhibitors [*therapeutic use]; 6. Randomized Controlled Trials as Topic; 7. Thrombosis [*prevention & control];
MESH terms:
Mirror therapy for improving motor function after stroke
1. *Recovery of Function; 2. Activities of Daily Living; 3. Exercise Movement Techniques [instrumentation, *methods]; 4. Functional Laterality [physiology]; 5. Paresis [etiology, *rehabilitation]; 6. Randomized Controlled Trials as Topic; 7. Stroke [complications]; 8. Stroke Rehabilitation [*methods];
MESH terms:
Remote ischaemic conditioning for preventing and treating ischaemic stroke
1. *Neuroprotection; 2. Bias; 3. Cerebral Arterial Diseases [complications]; 4. Extremities [blood supply]; 5. Ischemic Preconditioning [*methods, mortality]; 6. Randomized Controlled Trials as Topic; 7. Stroke [mortality, prevention & control, *therapy]; 8. Thrombolytic Therapy [mortality];
MESH terms:
Controlled hypotension versus normotensive resuscitation strategy for people with ruptured abdominal aortic aneurysm
1. *Blood Pressure; 2. *Hypotension, Controlled; 3. Aortic Aneurysm, Abdominal [*complications]; 4. Aortic Rupture [*complications]; 5. Resuscitation [*methods]; 6. Shock, Hemorrhagic [etiology, *therapy]; 7. Systole;
MESH terms:
Extracorporeal shock wave therapy for the healing and management of venous leg ulcers
1. Extracorporeal Shockwave Therapy [*methods]; 2. Leg Ulcer [*therapy]; 3. Varicose Ulcer [therapy]; 4. Wound Healing;
MESH terms:
Transradial versus transfemoral approach for diagnostic coronary angiography and percutaneous coronary intervention in people with coronary artery disease
1. *Femoral Artery; 2. *Radial Artery; 3. Cardiac Catheterization [adverse effects, *methods]; 4. Coronary Angiography [*methods]; 5. Coronary Artery Disease [*diagnostic imaging, mortality, *surgery]; 6. Myocardial Infarction [etiology, mortality]; 7. Percutaneous Coronary Intervention [adverse effects, *methods];
MESH terms:
First‐line drugs for hypertension
1. Adrenergic beta‐Antagonists [therapeutic use]; 2. Angiotensin‐Converting Enzyme Inhibitors [therapeutic use]; 3. Antihypertensive Agents [adverse effects, *therapeutic use]; 4. Calcium Channel Blockers [therapeutic use]; 5. Coronary Disease [prevention & control]; 6. Hypertension [*drug therapy, mortality]; 7. Randomized Controlled Trials as Topic; 8. Sodium Chloride Symporter Inhibitors [therapeutic use]; 9. Stroke [prevention & control]; 10. Thiazides [adverse effects, therapeutic use];
MESH terms:
Supervised exercise therapy versus home‐based exercise therapy versus walking advice for intermittent claudication
1. *Directly Observed Therapy; 2. Exercise Therapy [*methods, psychology]; 3. Intermittent Claudication [psychology, *therapy]; 4. Mental Health; 5. Pain Management [psychology]; 6. Pain Measurement; 7. Randomized Controlled Trials as Topic; 8. *Walking;
MESH terms:
Perioperative beta‐blockers for preventing surgery‐related mortality and morbidity
1. Adrenergic beta-Antagonists [adverse effects, *therapeutic use]; 2. Anesthesia, General; 3. Arrhythmias, Cardiac [mortality, prevention & control]; 4. Bradycardia [chemically induced]; 5. Cardiovascular Diseases [chemically induced, mortality, *prevention & control]; 6. Cardiovascular Surgical Procedures [adverse effects, mortality]; 7. Cause of Death; 8. Cerebrovascular Disorders [mortality, prevention & control]; 9. Hypotension [chemically induced, mortality, prevention & control]; 10. Myocardial Infarction [mortality, prevention & control]; 11. Myocardial Ischemia [mortality, prevention & control]; 12. Postoperative Complications [mortality, *prevention & control]; 13. Randomized Controlled Trials as Topic; 14. Surgical Procedures, Operative [*adverse effects, mortality];
MESH terms:
Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation
1. Atrial Fibrillation [*complications]; 2. Embolism [*prevention & control]; 3. Factor Xa Inhibitors [*therapeutic use]; 4. Intracranial Embolism [*prevention & control]; 5. Randomized Controlled Trials as Topic; 6. Stroke [prevention & control]; 7. Vitamin K [*antagonists & inhibitors];
MESH terms:
Fluvastatin for lowering lipids
1. Cholesterol [*blood]; 2. Cholesterol, LDL [blood]; 3. Controlled Before‐After Studies; 4. Dose‐Response Relationship, Drug; 5. Fatty Acids, Monounsaturated [*administration & dosage]; 6. Fluvastatin; 7. Hydroxymethylglutaryl‐CoA Reductase Inhibitors [*administration & dosage]; 8. Indoles [*administration & dosage]; 9. Randomized Controlled Trials as Topic; 10. Triglycerides [blood];
MESH terms:
Treatment for superficial thrombophlebitis of the leg
1. Anti‐Inflammatory Agents, Non‐Steroidal [*therapeutic use]; 2. Anticoagulants [*therapeutic use]; 3. Factor Xa Inhibitors [therapeutic use]; 4. Fondaparinux; 5. Hemorrhage [chemically induced]; 6. Heparin, Low‐Molecular‐Weight [*therapeutic use]; 7. Polysaccharides [therapeutic use]; 8. Randomized Controlled Trials as Topic; 9. Rivaroxaban [therapeutic use]; 10. Stockings, Compression; 11. Thrombectomy; 12. Thromboembolism [prevention & control]; 13. Thrombophlebitis [drug therapy, surgery, *therapy]; 14. Venous Thromboembolism [*prevention & control];
MESH terms:
Graft type for femoro‐popliteal bypass surgery
1. Arterial Occlusive Diseases [*surgery]; 2. Blood Vessel Prosthesis Implantation; 3. Femoral Artery [*surgery]; 4. Intermittent Claudication [surgery]; 5. Leg [*blood supply]; 6. Polyethylene Terephthalates; 7. Polytetrafluoroethylene; 8. Popliteal Artery [*surgery]; 9. Randomized Controlled Trials as Topic; 10. Saphenous Vein [*transplantation]; 11. Transplantation, Autologous; 12. Umbilical Veins [*transplantation]; 13. Vascular Surgical Procedures;
MESH terms:
Pulmonary artery perfusion versus no perfusion during cardiopulmonary bypass for open heart surgery in adults
1. *Pulmonary Artery; 2. Cardiac Surgical Procedures [*adverse effects]; 3. Cardiopulmonary Bypass [*adverse effects]; 4. Cause of Death; 5. Lung [*blood supply]; 6. Lung Diseases [etiology, *prevention & control]; 7. Organ Preservation Solutions; 8. Oxygen Consumption; 9. Perfusion [*methods]; 10. Postoperative Complications [*prevention & control]; 11. Pulmonary Circulation; 12. Randomized Controlled Trials as Topic;
MESH terms:
Exercise‐based cardiac rehabilitation for adults with stable angina
1. *Exercise; 2. Angina, Stable [*rehabilitation]; 3. Cardiac Rehabilitation [*methods]; 4. Cause of Death; 5. Hospitalization [statistics & numerical data]; 6. Myocardial Infarction [epidemiology]; 7. Publication Bias; 8. Quality of Life; 9. Randomized Controlled Trials as Topic;
MESH terms:
Antibiotic therapy for preventing infections in people with acute stroke
1. Anti-Bacterial Agents [*therapeutic use]; 2. Antibiotic Prophylaxis [methods]; 3. Bacterial Infections [mortality, *prevention & control]; 4. Brain Ischemia [complications]; 5. Pneumonia [epidemiology]; 6. Randomized Controlled Trials as Topic; 7. Stroke [*complications, mortality]; 8. Urinary Tract Infections [epidemiology];
MESH terms:
Prostanoids for critical limb ischaemia
1. Alprostadil [therapeutic use]; 2. Amputation, Surgical [statistics & numerical data]; 3. Epoprostenol [therapeutic use]; 4. Iloprost [therapeutic use]; 5. Ischemia [*drug therapy, mortality]; 6. Leg [*blood supply, surgery]; 7. Leg Ulcer [drug therapy]; 8. Nafronyl [therapeutic use]; 9. Nicotinic Acids [therapeutic use]; 10. Pentoxifylline [therapeutic use]; 11. Peripheral Vascular Diseases [*drug therapy]; 12. Prostaglandins [adverse effects, *therapeutic use]; 13. Randomized Controlled Trials as Topic; 14. Vasodilator Agents [therapeutic use];
MESH terms:
Home versus in‐patient treatment for deep vein thrombosis
1. *Home Care Services; 2. *Hospitalization; 3. Cost‐Benefit Analysis; 4. Fibrinolytic Agents [*therapeutic use]; 5. Hemorrhage [chemically induced]; 6. Heparin [adverse effects, *therapeutic use]; 7. Heparin, Low‐Molecular‐Weight [adverse effects, therapeutic use]; 8. Randomized Controlled Trials as Topic; 9. Recurrence; 10. Secondary Prevention; 11. Thrombolytic Therapy [standards]; 12. Venous Thrombosis [*drug therapy, mortality];
MESH terms:
Exercise for intermittent claudication
1. Amputation, Surgical [statistics & numerical data]; 2. Ankle Brachial Index; 3. Exercise Therapy [*methods]; 4. Intermittent Claudication [*therapy]; 5. Pain Management [methods]; 6. Quality of Life; 7. Randomized Controlled Trials as Topic; 8. Time Factors; 9. Walking;
MESH terms:
Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with unprovoked venous thromboembolism
1. *Secondary Prevention; 2. Administration, Oral; 3. Anticoagulants [*administration & dosage, adverse effects]; 4. Aspirin [administration & dosage, adverse effects]; 5. Hemorrhage [chemically induced]; 6. Myocardial Infarction [epidemiology]; 7. Randomized Controlled Trials as Topic; 8. Recurrence; 9. Rivaroxaban [administration & dosage, adverse effects]; 10. Stroke [epidemiology]; 11. Venous Thromboembolism [drug therapy, mortality, *prevention & control]; 12. Warfarin [administration & dosage, adverse effects];
MESH terms:
Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular events
1. Aspirin [adverse effects, *therapeutic use]; 2. Cardiovascular Diseases [mortality, *prevention & control]; 3. Clopidogrel; 4. Drug Therapy, Combination [adverse effects, methods]; 5. Hemorrhage [chemically induced]; 6. Platelet Aggregation Inhibitors [adverse effects, *therapeutic use]; 7. Randomized Controlled Trials as Topic; 8. Ticlopidine [adverse effects, *analogs & derivatives, therapeutic use];
MESH terms:
Calcium channel blockers for primary and secondary Raynaud's phenomenon
1. Calcium Channel Blockers [administration & dosage, *therapeutic use]; 2. Dihydropyridines [administration & dosage, therapeutic use]; 3. Nifedipine [administration & dosage, therapeutic use]; 4. Pain Management; 5. Placebos [therapeutic use]; 6. Publication Bias; 7. Randomized Controlled Trials as Topic; 8. Raynaud Disease [*drug therapy, etiology]; 9. Severity of Illness Index;
MESH terms:
Thrombolysis for acute upper extremity deep vein thrombosis
1. Acute Disease; 2. Thrombolytic Therapy [*methods]; 3. Upper Extremity Deep Vein Thrombosis [*drug therapy];
MESH terms:
Pentasaccharides for the treatment of deep vein thrombosis
1. Anticoagulants [administration & dosage, adverse effects, *therapeutic use]; 2. Biotin [administration & dosage, adverse effects, *analogs & derivatives, therapeutic use]; 3. Fondaparinux; 4. Hemorrhage [chemically induced]; 5. Heparin, Low‐Molecular‐Weight [therapeutic use]; 6. Oligosaccharides [administration & dosage, adverse effects, *therapeutic use]; 7. Polysaccharides [administration & dosage, adverse effects, *therapeutic use]; 8. Randomized Controlled Trials as Topic; 9. Recurrence; 10. Time Factors; 11. Venous Thrombosis [*drug therapy];
MESH terms:
Virtual reality for stroke rehabilitation
1. *Video Games; 2. Activities of Daily Living; 3. Gait; 4. Postural Balance; 5. Psychomotor Performance; 6. Quality of Life; 7. Randomized Controlled Trials as Topic; 8. Stroke [psychology]; 9. Stroke Rehabilitation [*methods]; 10. Therapy, Computer‐Assisted [*methods]; 11. Upper Extremity; 12. User‐Computer Interface;
MESH terms:
Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease
1. Administration, Oral; 2. Anticoagulants [adverse effects, *therapeutic use]; 3. Antithrombins [adverse effects, therapeutic use]; 4. Atrial Fibrillation [*complications]; 5. Dabigatran [adverse effects, therapeutic use]; 6. Embolism [*prevention & control]; 7. Hemorrhage [chemically induced, epidemiology]; 8. Pyrazoles [adverse effects, therapeutic use]; 9. Pyridines [adverse effects, therapeutic use]; 10. Pyridones [adverse effects, therapeutic use]; 11. Randomized Controlled Trials as Topic; 12. Renal Insufficiency, Chronic [*complications]; 13. Rivaroxaban [adverse effects, therapeutic use]; 14. Stroke [*prevention & control]; 15. Thiazoles [adverse effects, therapeutic use]; 16. Warfarin [adverse effects, therapeutic use];
MESH terms:
Adenosine versus intravenous calcium channel antagonists for supraventricular tachycardia
1. Adenosine [adverse effects, *therapeutic use]; 2. Anti‐Arrhythmia Agents [adverse effects, *therapeutic use]; 3. Calcium Channel Blockers [adverse effects, *therapeutic use]; 4. Emergency Service, Hospital [statistics & numerical data]; 5. Hypotension [chemically induced]; 6. Randomized Controlled Trials as Topic; 7. Tachycardia, Supraventricular [*drug therapy]; 8. Verapamil [adverse effects, therapeutic use];
MESH terms:
Compression therapy for prevention of post‐thrombotic syndrome
1. *Bandages; 2. Postthrombotic Syndrome [etiology, *prevention & control]; 3. Quality of Life; 4. Randomized Controlled Trials as Topic; 5. Venous Thrombosis [complications];
MESH terms:
Interventions for treating tuberculous pericarditis
1. Adrenal Cortex Hormones [therapeutic use]; 2. Antitubercular Agents [therapeutic use]; 3. Cause of Death; 4. Colchicine [therapeutic use]; 5. Drainage; 6. HIV Seronegativity; 7. HIV Seropositivity [drug therapy]; 8. Immunotherapy; 9. Pericardiectomy; 10. Pericarditis, Tuberculous [complications, *drug therapy, mortality, *surgery]; 11. Pericardium [surgery]; 12. Randomized Controlled Trials as Topic;
MESH terms:
Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome
1. Acute Coronary Syndrome [mortality, *therapy]; 2. Cause of Death; 3. *Drug-Eluting Stents [adverse effects]; 4. Randomized Controlled Trials as Topic; 5. *Stents [adverse effects];
MESH terms:
Treadmill training and body weight support for walking after stroke
1. *Walking Speed; 2. Body Weight; 3. Exercise Therapy [instrumentation, *methods]; 4. Orthotic Devices; 5. Patient Dropouts [statistics & numerical data]; 6. Randomized Controlled Trials as Topic; 7. Stroke Rehabilitation [*methods]; 8. Walking; 9. Weight‐Bearing;
MESH terms:
Pharmacotherapy for hypertension in adults aged 18 to 59 years
1. Antihypertensive Agents [adverse effects, *therapeutic use]; 2. Bendroflumethiazide [therapeutic use]; 3. Blood Pressure [drug effects]; 4. Cause of Death; 5. Coronary Disease [mortality, prevention & control]; 6. Hypertension [*drug therapy, mortality]; 7. Methyldopa [therapeutic use]; 8. Myocardial Infarction [mortality, prevention & control]; 9. Patient Dropouts [statistics & numerical data]; 10. Propranolol [therapeutic use]; 11. Randomized Controlled Trials as Topic; 12. Stroke [mortality, prevention & control];
MESH terms:
Blood pressure targets for hypertension in older adults
1. Antihypertensive Agents [*therapeutic use]; 2. Blood Pressure [*drug effects]; 3. Blood Pressure Determination; 4. Cardiovascular Diseases [epidemiology]; 5. Cause of Death; 6. Hospitalization [statistics & numerical data]; 7. Hypertension [*drug therapy, mortality]; 8. Patient Dropouts [statistics & numerical data]; 9. Randomized Controlled Trials as Topic; 10. Reference Values; 11. Stroke [epidemiology]; 12. Systole;
MESH terms:
Low molecular weight heparin for prevention of venous thromboembolism in patients with lower‐limb immobilization
1. Anticoagulants [adverse effects, *therapeutic use]; 2. Cause of Death; 3. Hemorrhage [chemically induced]; 4. Heparin, Low‐Molecular‐Weight [adverse effects, *therapeutic use]; 5. Immobilization [*adverse effects]; 6. Leg Injuries [*therapy]; 7. Pulmonary Embolism [epidemiology, prevention & control]; 8. Randomized Controlled Trials as Topic; 9. Venous Thromboembolism [*prevention & control]; 10. Venous Thrombosis [epidemiology, prevention & control];
MESH terms:
Vitamin K antagonists versus low‐molecular‐weight heparin for the long term treatment of symptomatic venous thromboembolism
1. Anticoagulants [adverse effects, *therapeutic use]; 2. Hemorrhage [chemically induced, epidemiology]; 3. Heparin, Low‐Molecular‐Weight [adverse effects, *therapeutic use]; 4. Incidence; 5. Odds Ratio; 6. Randomized Controlled Trials as Topic; 7. Recurrence; 8. Venous Thromboembolism [*drug therapy, mortality]; 9. Venous Thrombosis [drug therapy]; 10. Vitamin K [*antagonists & inhibitors];